The Heartburn Drug That Just Unlocked 60 Million New Patients
Phathom's Voquezna just became the first and only drug with an FDA label for non-erosive GERD, the most common form of heartburn that PPIs consistently fail to treat. With 50-70% of all GERD patients falling into this category, the approval could reshape a market that hasn't seen real innovation in three decades.
Roughly 60% of people with chronic heartburn get told the same thing: take a PPI and deal with it. The problem? For a huge chunk of them, PPIs barely work. Now there's finally a drug approved specifically for their condition, and it could reshape one of the biggest markets in gastroenterology.
Phathom Pharmaceuticals just scored its third FDA approval for Voquezna (vonoprazan), this time expanding the label to cover non-erosive gastroesophageal reflux disease, or NERD, in adults. It's a clunky acronym for a massive patient population: people who suffer from persistent heartburn but don't show visible damage to their esophagus on an endoscopy.
And it matters more than you might think.
The Biggest Slice of the GERD Pie
GERD affects tens of millions of Americans. But not all GERD is created equal. The non-erosive variety (NERD) accounts for 50% to 70% of all GERD cases in Western populations, making it the single largest subgroup. Some estimates peg NERD prevalence at 11% to 12% of the general population.
Phathom itself has cited roughly 20 million people in the U.S. being treated for acid-related stomach problems. NERD patients represent the majority of that number. Yet until now, no drug carried an FDA-approved label specifically for heartburn relief in non-erosive GERD.
That's like having a football stadium full of patients and no play designed for them.
Why PPIs Keep Dropping the Ball
Proton pump inhibitors (PPIs) like omeprazole and lansoprazole have dominated heartburn treatment for over three decades. They're cheap. They're everywhere. They're also surprisingly mediocre for NERD patients.
A systematic review found that the symptomatic response rate to PPIs was just 36.7% in NERD, compared with 55.5% in erosive GERD. That's a 20 to 30 percentage point gap. If PPIs were a basketball player, they'd be shooting under 40% from the field for the majority of the team's possessions.
Part of the problem is biological. Some NERD patients have symptoms driven by non-acid reflux or esophageal hypersensitivity, meaning acid suppression alone can't fully solve the issue. But for many, the real issue is that PPIs just aren't powerful or consistent enough. They need to be activated by acid, they require meal timing, and their effectiveness varies wildly depending on a patient's genetics (specifically CYP2C19 enzyme variants).
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Voquezna sidesteps all of those limitations.
A Different Kind of Acid Blocker
Voquezna belongs to a new drug class called potassium-competitive acid blockers (PCABs). Think of it this way: both PPIs and PCABs target the same proton pump in your stomach that produces acid. But PPIs are like a slow-drying glue; they irreversibly bind to the pump and need acidic conditions to activate, which means they take days to reach full strength and require careful meal timing.
Voquezna works more like a key jammed into a lock. It reversibly blocks the potassium-binding site on the pump, shutting down acid production almost immediately. It doesn't need acid to activate. It doesn't care whether you've eaten. And it works on both active and resting pumps, which gives it stronger, more consistent acid suppression, including at night when breakthrough heartburn is most annoying.
The result: faster onset from the first dose, longer-lasting acid control, and far less variability between patients.
The Data That Got It Across the Finish Line
The approval was built on a Phase 3 trial called pHalcon-NERD-301, a randomized, double-blind, placebo-controlled study of 772 adults with confirmed non-erosive GERD. Patients received either vonoprazan 10 mg, vonoprazan 20 mg, or placebo once daily.
The primary endpoint was the percentage of 24-hour heartburn-free days over four weeks. Voquezna delivered: patients on the drug experienced a mean of 45% heartburn-free days, compared with just 28% on placebo (p < 0.001). The median gap was even more dramatic, with Voquezna patients hitting 48% heartburn-free days versus 17% for placebo.
Nighttime results were equally compelling. By week four, patients on vonoprazan 10 mg reported 59.9% heartburn-free nights, compared with 43.3% for placebo. Improvements showed up after the very first dose and held steady through a 24-week extension period.
On safety, the profile was clean: the most common side effects (abdominal pain, constipation, diarrhea, nausea) each occurred in about 2% of patients. No major new safety signals emerged during the extension phase.
A Commercial Machine That's Already Humming
This isn't Phathom's first rodeo with Voquezna. The drug launched in Q4 2023 for erosive GERD and H. pylori infection, and the commercial ramp has been impressive.
Full-year 2025 net revenues hit $175.1 million, more than tripling the $55.3 million from 2024. By Q1 2026, the franchise was pulling in $58.3 million per quarter, with GERD indications identified as the primary growth driver. Over 1.1 million cumulative prescriptions had been filled by early 2026, and Voquezna now covers more than 80% of U.S. commercial insurance lives.
Phathom has publicly guided toward peak sales potential north of $3 billion across all indications. With the NERD label now in hand, that number starts to look less aspirational and more like a roadmap. The company has also been eyeing overall profitability in 2026, with quarterly losses narrowing as Voquezna revenue scales.
The $650 Elephant in the Room
Of course, there's a catch. Voquezna carries a retail price of roughly $675 or more for a 30-day supply. Generic omeprazole costs roughly the price of a nice sandwich. That price premium is the single biggest headwind.
Payers will inevitably impose step-therapy requirements, meaning patients may need to fail on a PPI before insurers will cover Voquezna. But Phathom has a few things working in its favor. First, this is a physician-driven market where clinical differentiation matters. Second, Voquezna's clinical superiority to PPIs (it actually beat lansoprazole head-to-head in erosive GERD trials) gives doctors a real reason to prescribe it. Third, the FDA granted New Chemical Entity exclusivity through May 2032, meaning no generic PCAB competition in the U.S. for the rest of the decade.
That's a long runway with no one else on the tarmac.
What This Means for the GERD Landscape
Voquezna is now the first and only FDA-approved treatment specifically labeled for non-erosive GERD heartburn relief in the United States. It's also the first major innovation in GERD therapy in roughly 30 years. For the millions of patients who've been told to just keep taking PPIs that don't really work, that's a meaningful shift.
Wall Street generally views the NERD expansion as transformational but execution-dependent. The addressable market is enormous, and the clinical and IP position is strong. The open questions are all about commercial blocking and tackling: can Phathom convert enough PPI-frustrated patients, secure broad formulary access, and educate both GI specialists and primary care doctors fast enough to justify the valuation?
With a $175 million revenue base, a triple-digit growth trajectory, and now the largest GERD indication on the label, Phathom has built something that looks increasingly hard to ignore. The NERD approval doesn't just add a line to the prescribing information. It fundamentally changes the size of the opportunity.
For 30 years, GERD patients without erosions got hand-me-down treatments designed for a different condition. Voquezna is the first drug that's actually theirs.
Clinical & Regulatory
4 min read
The Ruling That Just Killed 60,000 Lawsuits
The Supreme Court just ruled that federal law blocks most Roundup cancer lawsuits, potentially wiping out 60,000+ pending claims in a landmark win for Bayer. The decision could reshape how mass tort litigation works for every chemical and drug company in America.
